Short answer
LB PHARMACEUTICALS INC (LBRX) filed an 8-K current report with the SEC on July 29, 2026 reporting Item EX-99.1 (Exhibit EX-99.1), Item 1.01 (Entry into a Material Definitive Agreement), Item 7.01 (Regulation FD Disclosure), Item 3.02 (Unregistered Sales of Equity Securities). Private placement targeting approximately $150.0 million gross proceeds, strengthening funding for LB-102 development and corporate needs.
LB PHARMACEUTICALS INC 8-K event analysis
AI summary of each reported item and its exhibits
Item 1.01 · Entry into a Material Definitive Agreement
- Private placement targeting approximately $150.0 million gross proceeds, strengthening funding for LB-102 development and corporate needs
- Issuance of 3,577,560 common shares plus pre-funded warrants for 715,513 shares, creating immediate dilution and potential additional dilution
- Financing supports expansion into schizophrenia negative symptoms and Alzheimer’s agitation/psychosis, with potential trial initiation in the second half of 2027
- Pre-funded warrants exercisable immediately at $0.0001 per share, with no expiration and 4.99% or 9.99% ownership caps
- Resale registration required within 90 days of closing, potentially increasing future tradable share supply
Item 3.02 · Unregistered Sales of Equity Securities
- Private placement shares issued under Securities Act Section 4(a)(2) exemption
- Restricted securities, not registered for public resale
- Transaction limited to investors providing private-placement representations
- Potential future dilution and resale overhang for existing shareholders
Item 7.01 · Regulation FD Disclosure
- July 29, 2026 press release announces a private placement
- Financing likely provides capital for corporate purposes, with dilution and funding terms requiring review of Exhibit 99.1
Item EX-99.1 · Exhibit EX-99.1
- $150 million private placement at $34.94 per share, supporting LB-102 development and corporate funding
- 3,577,560 shares plus pre-funded warrants for 715,513 shares, creating material potential dilution
- Proceeds targeted at LB-102 expansion into schizophrenia negative symptoms and Alzheimer’s agitation or psychosis
- Financing includes new and existing institutional investors, strengthening near-term funding for ongoing Phase 3 and Phase 2 trials
- Resale registration rights may increase future trading supply once registration becomes effective
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other LB PHARMACEUTICALS INC 8-K filings
Get the next LBRX 8-K as it lands
Follow LBRX for push alerts, or ask the research agent what this filing means.